NeuroBo reports FY 2023 net loss $12.5M; cash $22.4M; DA-1726 Phase 1 to dose Q2 2024

MetaVia Inc.

Net loss $12.5M ($2.46 per share) vs $14.0M in FY 2022; R&D spend rose to $9.2M.
Cash $22.4M as of Dec. 31, 2023, expected to fund operations into Q4 2024.
DA-1726 Phase 1 obesity trial: first site IRB approved; first patient dosing expected Q2 2024.
DA-1241 Phase 2a MASH trial: SRC approval to continue; full data expected H2 2024.
Marshall Woodworth appointed permanent CFO; company regained Nasdaq compliance after reverse split.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MetaVia Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2023

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-004166

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.